Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Arformoterol Tartrate Inhalation Solution

Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)

DRUG

Arformoterol Tartrate Inhalation Solution

Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)

DRUG

Placebo

Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day

Trial Locations (4)

Philadelphia

Spartanburg

Portland

Medford

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00571428 - Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD | Biotech Hunter | Biotech Hunter